Open AccessIndividualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
Author(s) -
Sofie Van Binnebeek,
Kristof Baete,
B Vanbilloen,
Christelle Terwinghe,
Michel Koole,
Felix M. Mottaghy,
Paul M. Clément,
Luc Mortelmans,
Karin Haustermans,
Eric Van Cutsem,
Alfons Verbruggen,
Kris Bogaerts,
Chris Verslype,
Christophe M. Deroose
Publication year - 2014
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-013-2670-x
Subject(s) - radionuclide therapy , renal function , medicine , kidney , urology , toxicity , kidney disease , nuclear medicine
Assessment of kidney function evolution after (90)Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom